Research programme: cardiovascular disease therapy - SEQUENOM

Drug Profile

Research programme: cardiovascular disease therapy - SEQUENOM

Latest Information Update: 04 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SEQUENOM
  • Class Peptides; Small molecules
  • Mechanism of Action Genetic transcription modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 29 Jul 2004 SEQUENOM has terminated its drug discovery efforts
  • 08 Oct 2001 Gemini Genomics has been acquired by SEQUENOM
  • 30 Mar 2001 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top